Career Development Award in HER2
Limited submission
Career Development Award in HER2 supports early-career pathologists researching HER2 testing in solid tumors beyond breast and gastric cancer to improve patient selection for anti-HER2 therapies.
Browse similar grants
Funder: College of American Pathologists Foundation
Due Dates: November 2, 2026 (Application deadline)
Funding Amounts: Up to $120,000 USD for a 12-month project, February 2027–February 2028
Summary: Supports early-career pathologists conducting quantitative research to optimize and validate HER2 IHC assays in solid tumors beyond breast and gastric cancer.
Key Information: Only one proposal per institution is permitted, with support from the Chair of the Pathology Department.
Description
The College of American Pathologists Foundation supports early-career investigators conducting quantitative pathology research to optimize and validate HER2 immunohistochemistry (IHC) assays in solid tumors beyond breast and gastric cancer. The award addresses gaps in standardized testing and seeks evidence to improve consistent, accurate patient selection for anti-HER2 antibody-drug conjugate (ADC) therapies.
Projects should use tumor-specific criteria and rigorous analytic validation methods. Three priority areas are colorectal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. Additional objectives may examine HER2 expression patterns, correlations with other diagnostic modalities such as ISH or NGS, or evidence-based recommendations for potential future CAP testing guidelines. Proposals should combine research with mentored experience and skills development for the early-career pathologist.
